Core Viewpoint - Hai Jiaya Medical (06078) has released its 2025 performance forecast, indicating a potential revenue decline but with signs of operational resilience and future growth opportunities [1][4]. Financial Performance - For the second half of 2025, the company expects revenue between 20.1 billion to 20.6 billion yuan, representing a year-on-year decline of 0-3% [1][4]. - Adjusted net profit is projected to be approximately 1.88 billion to 2.28 billion yuan, with a year-on-year change of -7% to +13% [1][4]. - Operating cash flow is anticipated to grow by 36% to 53% year-on-year [1][4]. Market Position and Strategy - The company's hospitals are evenly distributed across the country, which supports stable revenue growth in the second half of 2025 [1][4]. - Looking ahead to 2026, the impact of DRGs payment reform on average hospitalization costs is expected to diminish, potentially leading to positive revenue growth [1][4]. Analyst Insights - Citic Securities believes that despite the earnings warning, the decline in performance has likely reached its bottom [1][4]. - The company is expected to see a 2% year-on-year revenue decline in the second half, with adjusted net profit showing a recovery of 3% growth, indicating improving profitability resilience [1][4]. - Key growth drivers for 2026 include expanding non-national health insurance directory revenue, enhancing existing hospital utilization, and reducing debt levels to improve operational leverage and restore profit margins [1][4].

Core Viewpoint - Haijia Medical (06078) has seen a stock price increase of over 5%, currently at HKD 14.73, with a trading volume of HKD 87.87 million, following the release of its 2025 performance forecast [1] Financial Performance - For the second half of 2025, the company is expected to achieve revenue between RMB 20.1 billion and RMB 20.6 billion, representing a year-on-year decline of 0% to 3% [1] - Adjusted net profit is projected to be approximately RMB 1.88 billion to RMB 2.28 billion, reflecting a year-on-year change of -7% to +13% [1] - Operating cash flow is anticipated to grow by 36% to 53% year-on-year [1] Market Outlook - The company's hospitals are evenly distributed across the country, and revenue growth is expected to stabilize in 2025 [1] - For 2026, the impact of DRGs payment reform on average hospitalization costs is expected to diminish, potentially leading to positive revenue growth [1] Analyst Insights - Citic Securities believes that despite the earnings warning, the decline in performance has likely bottomed out [1] - The second half of 2025 is expected to see a 2% year-on-year revenue decline, with adjusted net profit anticipated to recover by 3%, indicating improving profitability resilience [1] - Key growth drivers for 2026 include expanding non-national health insurance directory revenue, enhancing existing hospital utilization rates, and reducing debt levels to improve operational leverage and restore profit margins [1]

Core Viewpoint - The company forecasts a revenue of approximately 40.0-40.5 billion yuan for 2025, representing a year-on-year decline of 9%-10%, with a net profit attributable to shareholders of about 1.4-2.0 billion yuan, down 66%-76% [1][2]. Financial Performance - In the second half of 2025, the company expects to achieve revenue of 20.1-20.6 billion yuan, a year-on-year decline of 0-3%, and an adjusted net profit of approximately 1.88-2.28 billion yuan, with a change of -7% to +13% [2][3]. - The operating cash flow for the second half of 2025 is projected to grow by 36%-53%, reaching approximately 4.8-5.4 billion yuan [2][3]. - The company anticipates a net cash flow from operating activities of about 9.4-10.0 billion yuan for 2025, reflecting a year-on-year increase of 33%-41% [1][2]. Business Strategy and Market Position - The company is focusing on deepening discipline construction and introducing AI to enhance operations, which is expected to improve revenue and patient visits in the second half of 2025 [2][3]. - The company plans to expand its overseas tumor diagnosis and treatment services, starting in 2025, primarily from its hospital in Chongqing, with potential growth into other hospitals [1][3]. - The company operates 16 hospitals and has ongoing projects that are expected to contribute to future growth, including the opening of new facilities [5]. Industry Trends - The impact of DRGs (Diagnosis-Related Groups) payment reform on average hospitalization costs is expected to diminish, allowing for a potential recovery in overall revenue growth in 2026 [3][4]. - The aging population in China is driving a continuous increase in demand for tumor diagnosis and treatment, positioning the company favorably as a leading comprehensive cancer hospital group [4]. Shareholder Confidence - The company's founder and associated parties have consistently increased their holdings, demonstrating confidence in the company's long-term development [5]. - The company has initiated a share repurchase plan, further indicating its commitment to shareholder returns and long-term growth [5]. Profit Forecast - The company has adjusted its profit forecasts for 2025-2027, expecting revenues of 40.02 billion yuan, 44.59 billion yuan, and 50.19 billion yuan, with respective year-on-year growth rates of -10.00%, 11.44%, and 12.55% [5].